Key result
Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) advancements have expanded its indication to patients aged 70 or higher with severe tricuspid aortic stenosis and suitable anatomy.
Why the study?
To summarize advancements in TAVI/TAVR, addressing next frontiers such as younger age at implantation, redo TAVI planning, and THV durability.
This review highlights the evolution of TAVI from high-risk patients to broader indications, emphasizing the importance of preprocedural planning, device selection, and future innovations like polymeric valves.
Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has come a long way since the first-in-human implant by Prof Cribier & colleagues in 2002. Initially a consideration for inoperable/high-surgical-risk patients, TAVI is now indicated in patients with severe tricuspid aortic stenosis and suitable anatomy aged 70 or higher. This has been made possible due to improvements in preprocedural planning, performance upgrades to and evolution of transcatheter heart valve (THV) systems and increasing operator experience. Younger age at index implantation, complexities of redo TAVI planning and methods to improve THV durability are the next frontiers. This review summarizes these advancements while emphasizing preprocedural planning, current guidelines, and individualized device selection, with a brief note on polymeric heart valves—developed to overcome the disadvantageous bioprosthetic dysfunction seen with current THVs.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) conducted a review in Severe tricuspid aortic stenosis. Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) was evaluated. Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) advancements have expanded its indication to patients aged 70 or higher with severe tricuspid aortic stenosis and suitable anatomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: